Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Targeted drug combination therapy design based on driver genes.

Zsákai L, Sipos A, Dobos J, Erős D, Szántai-Kis C, Bánhegyi P, Pató J, Őrfi L, Matula Z, Mikala G, Kéri G, Peták I, Vályi-Nagy I.

Oncotarget. 2019 Sep 3;10(51):5255-5266. doi: 10.18632/oncotarget.26985. eCollection 2019 Sep 3.

PMID:
31523388
2.

Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients.

Lovas S, Varga G, Farkas P, Masszi T, Wohner N, Bereczki Á, Adamkovich N, Borbényi Z, Szomor Á, Alizadeh H, Szaleczky E, Wolf K, Schneider T, Plander M, Szendrei T, Csacsovszki O, Csukly Z, Rajnics P, Egyed M, Nagy Z, Rejtő L, Illés Á, Mikala G, Váróczy L.

Int J Hematol. 2019 Aug 7. doi: 10.1007/s12185-019-02715-w. [Epub ahead of print]

PMID:
31392600
3.

Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patients.

Avivi I, Cohen YC, Suska A, Shragai T, Mikala G, Garderet L, Seny GM, Glickman S, Jayabalan DS, Niesvizky R, Gozzetti A, Wiśniewska-Piąty K, Waszczuk-Gajda A, Usnarska-Zubkiewicz L, Hus I, Guzicka R, Radocha J, Milunovic V, Davila J, Gentile M, Castillo JJ, Jurczyszyn A.

Am J Hematol. 2019 Oct;94(10):1132-1140. doi: 10.1002/ajh.25579. Epub 2019 Aug 13.

PMID:
31334859
4.

Real World Efficacy and Safety Results of Ixazomib Lenalidomide and Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program.

Varga G, Nagy Z, Demeter J, Kosztolányi S, Szomor Á, Alizadeh H, Deák B, Schneider T, Plander M, Szendrei T, Váróczy L, Illés Á, Bátai Á, Pető M, Mikala G.

Pathol Oncol Res. 2019 Feb 2. doi: 10.1007/s12253-019-00607-2. [Epub ahead of print]

PMID:
30712192
5.

[Corneal deposits in monoclonal gammopathy of undetermined significance. Review of the literature and case report].

Németh O, Tapasztó B, Tar S, Szabó V, Nagy ZZ, Tóth J, Hamed A, Mikala G, Szentmáry N.

Orv Hetil. 2018 Sep;159(39):1575-1583. doi: 10.1556/650.2018.31196. Review. Hungarian.

PMID:
30543127
6.

Skin-homing CD8+ T cells preferentially express GPI-anchored peptidase inhibitor 16, an inhibitor of cathepsin K.

Lupsa N, Érsek B, Horváth A, Bencsik A, Lajkó E, Silló P, Oszvald Á, Wiener Z, Reményi P, Mikala G, Masszi T, Buzás EI, Pós Z.

Eur J Immunol. 2018 Dec;48(12):1944-1957. doi: 10.1002/eji.201847552. Epub 2018 Nov 9.

PMID:
30365157
7.

Clinical characteristics and treatment outcomes in IgE multiple myeloma: A case-control study.

Jurczyszyn A, Castillo JJ, Vesole DH, Liu J, Avivi I, Waszczuk-Gajda A, Lech-Maranda E, Gentile M, Mikala G, Guerrero-Garcia T, Suska A, Gertz MA.

Am J Hematol. 2018 Sep;93(9):E238-E241. doi: 10.1002/ajh.25209. Epub 2018 Aug 6. No abstract available.

8.

Multiple Myeloma of the Central Nervous System: 13 Cases and Review of the Literature.

Varga G, Mikala G, Gopcsa L, Csukly Z, Kollai S, Balázs G, Botond T, Wohner N, Horváth L, Szombath G, Farkas P, Masszi T.

J Oncol. 2018 Apr 23;2018:3970169. doi: 10.1155/2018/3970169. eCollection 2018. Review.

9.

[Waldenström's macroglobulinemia and its individualized therapy options].

Szemlaky Z, Mikala G.

Orv Hetil. 2017 Oct;158(41):1604-1614. doi: 10.1556/650.2017.30868. Review. Hungarian.

PMID:
29025291
10.

Proteasome Subunit Beta Type 1 P11A Polymorphism Is a New Prognostic Marker in Multiple Myeloma.

Varga G, Mikala G, Kiss KP, Kosóczki É, Szabó E, Meggyesi N, Balassa K, Kövy P, Tegze B, Szombath G, Tordai A, Andrikovics H, Homolya L, Masszi T.

Clin Lymphoma Myeloma Leuk. 2017 Nov;17(11):734-742. doi: 10.1016/j.clml.2017.06.034. Epub 2017 Jun 30.

PMID:
28733196
11.

The adverse effect of FOPNL genomic variant is reversed by bortezomib-based treatment protocols in multiple myeloma.

Kiss KP, Varga G, Mikala G, Balassa K, Bors A, Kovy P, Meggyesi N, Kozma A, Csacsovszki O, Remenyi P, Valyi-Nagy I, Tordai A, Masszi T, Andrikovics H.

Leuk Lymphoma. 2018 Mar;59(3):710-716. doi: 10.1080/10428194.2017.1346250. Epub 2017 Jul 9.

PMID:
28691553
12.

Early Versus Delayed Autologous Stem Cell Transplantation and Interferon Maintenance in Multiple Myeloma: Single-Center Experience of 18 Years.

Remenyi P, Varga G, Mikala G, Reti M, Gopcsa L, Batai A, Csukly Z, Lengyel L, Torbagyi E, Barta A, Fabian J, Levai D, Szombath G, Andrikovics H, Masszi T.

Transplant Proc. 2016 Jan-Feb;48(1):177-84. doi: 10.1016/j.transproceed.2015.12.031.

PMID:
26915865
13.

[Management of multiple myeloma in Hungary in 2016].

Varga G, Mikala G, Váróczy L, Illés Á.

Orv Hetil. 2016 Jan 24;157(4):123-37. doi: 10.1556/650.2016.30341. Review. Hungarian.

PMID:
26772825
14.

[Prognostic factors in light chain amyloidosis].

Jávorniczky NR, Bodó I, Masszi T, Mikala G.

Orv Hetil. 2015 Sep 27;156(39):1577-84. doi: 10.1556/650.2015.30241. Hungarian.

PMID:
26550915
15.

NFKB1 -94ins/delATTG polymorphism is a novel prognostic marker in first line-treated multiple myeloma.

Varga G, Mikala G, Andrikovics H, Koszarska M, Balassa K, Ádám E, Kozma A, Tordai A, Masszi T.

Br J Haematol. 2015 Mar;168(5):679-88. doi: 10.1111/bjh.13197. Epub 2014 Nov 3.

PMID:
25363231
16.

[How long does a myeloma patient currently wait for the diagnosis in Hungary?].

Varga G, Mikala G, Andrikovics H, Masszi T.

Orv Hetil. 2014 Sep 28;155(39):1538-43. doi: 10.1556/OH.2014.30000. Hungarian.

PMID:
25240875
17.

Diffusion weighted magnetic resonance imaging demonstrates tumor response following palliative embolization of a recurrent shoulder plasmacytoma.

Bérczi V, Rudas G, Kozák LR, Györke T, Mikala G, Masszi T, Kalina I, Kaposi PN.

World J Surg Oncol. 2014 Aug 22;12:271. doi: 10.1186/1477-7819-12-271.

18.

Peripheral blood stem cell mobilization and engraftment after autologous stem cell transplantation with biosimilar rhG-CSF.

Reményi P, Gopcsa L, Marton I, Réti M, Mikala G, Pető M, Barta A, Bátai A, Farkas Z, Borbényi Z, Csukly Z, Bodó I, Fábián J, Király A, Lengyel L, Piukovics K, Torbágyi E, Masszi T.

Adv Ther. 2014 Apr;31(4):451-60. doi: 10.1007/s12325-014-0114-z. Epub 2014 Apr 1.

PMID:
24687301
19.

Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation.

Mohty M, Hübel K, Kröger N, Aljurf M, Apperley J, Basak GW, Bazarbachi A, Douglas K, Gabriel I, Garderet L, Geraldes C, Jaksic O, Kattan MW, Koristek Z, Lanza F, Lemoli RM, Mendeleeva L, Mikala G, Mikhailova N, Nagler A, Schouten HC, Selleslag D, Suciu S, Sureda A, Worel N, Wuchter P, Chabannon C, Duarte RF.

Bone Marrow Transplant. 2014 Jul;49(7):865-72. doi: 10.1038/bmt.2014.39. Epub 2014 Mar 31. Review.

PMID:
24686988
20.

Successful treatment of renal failure caused by multiple myeloma with HLA-identical living kidney and bone marrow transplantation: a case report.

Wagner L, Lengyel L, Mikala G, Reményi P, Piros L, Csomor J, Fábry L, Tordai A, Langer RM, Masszi T.

Transplant Proc. 2013;45(10):3705-7. doi: 10.1016/j.transproceed.2013.10.005.

PMID:
24315003
21.

Impact of polymorphic variation at 7p15.3, 3p22.1 and 2p23.3 loci on risk of multiple myeloma.

Martino A, Campa D, Jamroziak K, Reis RM, Sainz J, Buda G, García-Sanz R, Lesueur F, Marques H, Moreno V, Jurado M, Ríos R, Szemraj-Rogucka Z, Szemraj J, Tjønneland A, Overvad K, Vangsted AJ, Vogel U, Mikala G, Kádár K, Szombath G, Varkonyi J, Orciuolo E, Dumontet C, Gemignani F, Rossi AM, Landi S, Petrini M, Houlston RS, Hemminki K, Canzian F.

Br J Haematol. 2012 Sep;158(6):805-9. doi: 10.1111/j.1365-2141.2012.09244.x. Epub 2012 Jul 24. No abstract available.

22.

European data on stem cell mobilization with plerixafor in patients with nonhematologic diseases: an analysis of the European consortium of stem cell mobilization.

Worel N, Apperley JF, Basak GW, Douglas KW, Gabriel IH, Geraldes C, Hübel K, Jaksic O, Koristek Z, Lanza F, Lemoli R, Mikala G, Selleslag D, Duarte RF, Mohty M.

Transfusion. 2012 Nov;52(11):2395-400. doi: 10.1111/j.1537-2995.2012.03603.x. Epub 2012 Mar 13.

PMID:
22414093
23.

European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization.

Hübel K, Fresen MM, Apperley JF, Basak GW, Douglas KW, Gabriel IH, Geraldes C, Jaksic O, Koristek Z, Kröger N, Lanza F, Lemoli RM, Mikala G, Selleslag D, Worel N, Mohty M, Duarte RF.

Bone Marrow Transplant. 2012 Aug;47(8):1046-50. doi: 10.1038/bmt.2011.216. Epub 2011 Nov 14.

PMID:
22080971
24.

Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide.

Malard F, Kröger N, Gabriel IH, Hübel K, Apperley JF, Basak GW, Douglas KW, Geraldes C, Jaksic O, Koristek Z, Lanza F, Lemoli R, Mikala G, Selleslag D, Worel N, Mohty M, Duarte RF.

Biol Blood Marrow Transplant. 2012 Feb;18(2):314-7. doi: 10.1016/j.bbmt.2011.10.003. Epub 2011 Oct 13.

25.

Higher BMI is not a barrier to stem cell mobilization with standard doses of plerixafor and G-CSF.

Basak GW, Wiktor-Jedrzejczak W, Apperley JF, Douglas KW, Gabriel IH, Geraldes C, Hübel K, Jaksic O, Koristek Z, Lanza F, Lemoli R, Mikala G, Selleslag D, Worel N, Mohty M, Duarte RF.

Bone Marrow Transplant. 2012 Jul;47(7):1003-5. doi: 10.1038/bmt.2011.199. Epub 2011 Oct 10. No abstract available.

PMID:
21986638
26.

Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization.

Basak GW, Jaksic O, Koristek Z, Mikala G, Mayer J, Masszi T, Labar B, Wiktor-Jedrzejczak W; Central and Eastern European Leukemia Group (CELG).

Am J Hematol. 2011 Jul;86(7):550-3. doi: 10.1002/ajh.22038. Epub 2011 Jun 14.

27.

Plerixafor to rescue failing chemotherapy-based stem cell mobilization: it's not too late.

Basak GW, Mikala G, Koristek Z, Jaksic O, Basic-Kinda S, Cegledi A, Reti M, Masszi T, Mayer J, Giebel S, Hübel K, Labar B, Wiktor-Jedrzejczak W.

Leuk Lymphoma. 2011 Sep;52(9):1711-9. doi: 10.3109/10428194.2011.578312. Epub 2011 Jun 12.

PMID:
21663509
28.

Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous stem cells.

Basak GW, Jaksic O, Koristek Z, Mikala G, Basic-Kinda S, Mayer J, Masszi T, Giebel S, Labar B, Wiktor-Jedrzejczak W; Central and Eastern European Leukaemia Group (CELG).

Eur J Haematol. 2011 Jun;86(6):488-95. doi: 10.1111/j.1600-0609.2011.01605.x. Epub 2011 Apr 1.

PMID:
21410533
29.

Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA.

Douglas KW, Parker AN, Hayden PJ, Rahemtulla A, D'Addio A, Lemoli RM, Rao K, Maris M, Pagliuca A, Uberti J, Scheid C, Noppeney R, Cook G, Bokhari SW, Worel N, Mikala G, Masszi T, Taylor R, Treisman J.

Bone Marrow Transplant. 2012 Jan;47(1):18-23. doi: 10.1038/bmt.2011.9. Epub 2011 Feb 28.

PMID:
21358693
30.

JAK2 46/1 haplotype analysis in myeloproliferative neoplasms and acute myeloid leukemia.

Andrikovics H, Nahajevszky S, Koszarska M, Meggyesi N, Bors A, Halm G, Lueff S, Lovas N, Matrai Z, Csomor J, Rasonyi R, Egyed M, Varkonyi J, Mikala G, Sipos A, Kozma A, Adam E, Fekete S, Masszi T, Tordai A.

Leukemia. 2010 Oct;24(10):1809-13. doi: 10.1038/leu.2010.172. Epub 2010 Sep 2. No abstract available.

PMID:
20811399
31.

Targeted disruption of the voltage-dependent calcium channel alpha2/delta-1-subunit.

Fuller-Bicer GA, Varadi G, Koch SE, Ishii M, Bodi I, Kadeer N, Muth JN, Mikala G, Petrashevskaya NN, Jordan MA, Zhang SP, Qin N, Flores CM, Isaacsohn I, Varadi M, Mori Y, Jones WK, Schwartz A.

Am J Physiol Heart Circ Physiol. 2009 Jul;297(1):H117-24. doi: 10.1152/ajpheart.00122.2009. Epub 2009 May 8.

32.

HFE C282Y mutation as a genetic modifier influencing disease susceptibility for chronic myeloproliferative disease.

Andrikovics H, Meggyesi N, Szilvasi A, Tamaska J, Halm G, Lueff S, Nahajevszky S, Egyed M, Varkonyi J, Mikala G, Sipos A, Kalasz L, Masszi T, Tordai A.

Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):929-34. doi: 10.1158/1055-9965.EPI-08-0359. Epub 2009 Mar 3.

33.

Polymorphisms of TNF-alpha and LT-alpha genes in multiple myeloma.

Kádár K, Kovács M, Karádi I, Melegh B, Pocsai Z, Mikala G, Tordai A, Szilágyi A, Adány R, Füst G, Várkonyi J.

Leuk Res. 2008 Oct;32(10):1499-504. doi: 10.1016/j.leukres.2008.03.001. Epub 2008 Apr 10.

PMID:
18405969
34.

Endotoxins do not influence transplacental transmission of lymphotropic human herpesviruses and human papillomaviruses into amniotic fluid taken from healthy mothers before parturition in Hungary.

Younes SA, Csire M, Palyi B, Mikala G, Vályi-Nagy I, Cseh I, Benczik M, Jeney C, Takács T, Simon E, Fülöp V, Berencsi G, Fekete G, Visy M.

Acta Microbiol Immunol Hung. 2007 Sep;54(3):279-303.

PMID:
17896476
35.

Persistent long-term human herpesvirus 6 (HHV-6) infection in a patient with langerhans cell histiocytosis.

Csire M, Mikala G, Jákó J, Masszi T, Jánosi J, Dolgos J, Füle T, Tordai A, Berencsi G, Vályi-Nagy I.

Pathol Oncol Res. 2007;13(2):157-60. Epub 2007 Jul 3.

36.

[Role of the activating mutation Val617Phe of Janus kinase 2 gene in myeloproliferative diseases and significance of its detection].

Andrikovics H, Szilvási A, Meggyesi N, Király V, Halm G, Lueff S, Nahajevszky S, Mikala G, Sipos A, Lovas N, Csukly Z, Mátrai Z, Tamáska J, Tordai A, Masszi T.

Orv Hetil. 2007 Feb 4;148(5):203-10. Hungarian.

PMID:
17344140
37.

Detection of four lymphotropic herpesviruses in Hungarian patients with multiple myeloma and lymphoma.

Csire M, Mikala G, Peto M, Jánosi J, Juhász A, Tordai A, Jákó J, Domján G, Dolgos J, Berencsi G, Vályi-Nagy I.

FEMS Immunol Med Microbiol. 2007 Feb;49(1):62-7. Epub 2006 Nov 21.

38.

The L-type calcium channel in the heart: the beat goes on.

Bodi I, Mikala G, Koch SE, Akhter SA, Schwartz A.

J Clin Invest. 2005 Dec;115(12):3306-17. Review.

39.

[Molecular genetic methods for the prognostic criteria in multiple myeloma].

Mikala G, Jákó J, Vályi-Nagy I.

Orv Hetil. 2005 Aug 7;146(32):1673-82. Review. Hungarian.

PMID:
16149245
40.

[Soluble syndecan-1 levels in different plasma cell dyscrasias].

Jánosi J, Sebestyén A, Mikala G, Petö M, Jákó J, Domján G, Németh J, Kis Z, Kopper L, Vályi-Nagy I.

Orv Hetil. 2005 Jan 23;146(4):165-8. Hungarian.

PMID:
15751511
41.

Soluble syndecan-1 levels in different plasma cell dyscrasias and in different stages of multiple myeloma.

Jánosi J, Sebestyén A, Mikala G, Németh J, Kiss Z, Vályi-Nagy I.

Haematologica. 2004 Mar;89(3):370-1.

42.

[Proteasome inhibition: a new therapeutic approach for the treatment of multiple myeloma].

Mikala G, Jákó J, Vályi-Nagy I.

Orv Hetil. 2004 Jan 11;145(2):67-74. Review. Hungarian.

PMID:
14978877
43.

Characterization of auto-regulation of the human cardiac alpha1 subunit of the L-type calcium channel: importance of the C-terminus.

Mikala G, Bodi I, Klockner U, Varadi M, Varadi G, Koch SE, Schwartz A.

Mol Cell Biochem. 2003 Aug;250(1-2):81-9.

PMID:
12962146
44.

Mice with cardiac-specific sequestration of the beta-subunit of the L-type calcium channel.

Serikov V, Bodi I, Koch SE, Muth JN, Mikala G, Martinov SG, Haase H, Schwartz A.

Biochem Biophys Res Commun. 2002 May 24;293(5):1405-11.

PMID:
12054671
45.

[Role of thalidomide in the treatment of multiple myeloma].

Mikala G, Jákó J, Vályi-Nagy I.

Orv Hetil. 2001 Aug 19;142(33):1789-98. Review. Hungarian.

PMID:
11573449
46.

Parathyroid cells express dihydropyridine-sensitive cation currents and L-type calcium channel subunits.

Chang W, Pratt SA, Chen TH, Tu CL, Mikala G, Schwartz A, Shoback D.

Am J Physiol Endocrinol Metab. 2001 Jul;281(1):E180-9.

47.
48.

Cardiac-specific overexpression of the alpha(1) subunit of the L-type voltage-dependent Ca(2+) channel in transgenic mice. Loss of isoproterenol-induced contraction.

Muth JN, Yamaguchi H, Mikala G, Grupp IL, Lewis W, Cheng H, Song LS, Lakatta EG, Varadi G, Schwartz A.

J Biol Chem. 1999 Jul 30;274(31):21503-6.

50.

Human herpesvirus 8 in hematologic diseases.

Mikala G, Xie J, Berencsi G, Kiss C, Márton I, Domján G, Vályi-Nagy I.

Pathol Oncol Res. 1999;5(1):73-9. Review.

Supplemental Content

Loading ...
Support Center